AU2013318205B2 - Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor - Google Patents
Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor Download PDFInfo
- Publication number
- AU2013318205B2 AU2013318205B2 AU2013318205A AU2013318205A AU2013318205B2 AU 2013318205 B2 AU2013318205 B2 AU 2013318205B2 AU 2013318205 A AU2013318205 A AU 2013318205A AU 2013318205 A AU2013318205 A AU 2013318205A AU 2013318205 B2 AU2013318205 B2 AU 2013318205B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- combination
- amide
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703533P | 2012-09-20 | 2012-09-20 | |
| US61/703,533 | 2012-09-20 | ||
| US201261708070P | 2012-10-01 | 2012-10-01 | |
| US61/708,070 | 2012-10-01 | ||
| PCT/US2013/060292 WO2014047109A1 (en) | 2012-09-20 | 2013-09-18 | Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013318205A1 AU2013318205A1 (en) | 2015-02-26 |
| AU2013318205B2 true AU2013318205B2 (en) | 2016-05-19 |
Family
ID=49263471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013318205A Active AU2013318205B2 (en) | 2012-09-20 | 2013-09-18 | Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9532982B2 (enExample) |
| EP (1) | EP2897644B1 (enExample) |
| JP (1) | JP6212563B2 (enExample) |
| KR (1) | KR102220965B1 (enExample) |
| CN (1) | CN104661681B (enExample) |
| AU (1) | AU2013318205B2 (enExample) |
| BR (1) | BR112015004152A2 (enExample) |
| CA (1) | CA2880506C (enExample) |
| CY (1) | CY1120984T1 (enExample) |
| DK (1) | DK2897644T3 (enExample) |
| ES (1) | ES2686689T3 (enExample) |
| HR (1) | HRP20181413T1 (enExample) |
| HU (1) | HUE040520T2 (enExample) |
| IN (1) | IN2015DN00735A (enExample) |
| LT (1) | LT2897644T (enExample) |
| MX (1) | MX356278B (enExample) |
| PL (1) | PL2897644T3 (enExample) |
| PT (1) | PT2897644T (enExample) |
| RU (1) | RU2651023C2 (enExample) |
| SI (1) | SI2897644T1 (enExample) |
| WO (1) | WO2014047109A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172085A2 (en) * | 2014-05-09 | 2015-11-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| CN118593514B (zh) * | 2024-05-09 | 2025-05-27 | 西南医科大学附属医院 | 芳香化酶抑制剂在制备治疗黑色素瘤药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100105711A1 (en) * | 2008-09-10 | 2010-04-29 | Novartis Ag | Organic Compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201000947A1 (ru) * | 2007-12-20 | 2011-02-28 | Новартис Аг | Производные тиазола, применимые в качестве ингибиторов киназы pi3 |
| JP2011506563A (ja) * | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | ビスチアゾール誘導体、その製造方法および医薬品としてのその使用 |
| WO2010008847A2 (en) * | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
-
2013
- 2013-09-18 ES ES13770771.7T patent/ES2686689T3/es active Active
- 2013-09-18 PT PT13770771T patent/PT2897644T/pt unknown
- 2013-09-18 SI SI201331154T patent/SI2897644T1/sl unknown
- 2013-09-18 EP EP13770771.7A patent/EP2897644B1/en active Active
- 2013-09-18 LT LTEP13770771.7T patent/LT2897644T/lt unknown
- 2013-09-18 BR BR112015004152A patent/BR112015004152A2/pt not_active IP Right Cessation
- 2013-09-18 DK DK13770771.7T patent/DK2897644T3/en active
- 2013-09-18 RU RU2015111171A patent/RU2651023C2/ru active
- 2013-09-18 AU AU2013318205A patent/AU2013318205B2/en active Active
- 2013-09-18 JP JP2015533141A patent/JP6212563B2/ja active Active
- 2013-09-18 HR HRP20181413TT patent/HRP20181413T1/hr unknown
- 2013-09-18 HU HUE13770771A patent/HUE040520T2/hu unknown
- 2013-09-18 KR KR1020157006708A patent/KR102220965B1/ko active Active
- 2013-09-18 IN IN735DEN2015 patent/IN2015DN00735A/en unknown
- 2013-09-18 MX MX2015003657A patent/MX356278B/es active IP Right Grant
- 2013-09-18 PL PL13770771T patent/PL2897644T3/pl unknown
- 2013-09-18 CN CN201380049140.1A patent/CN104661681B/zh active Active
- 2013-09-18 US US14/429,367 patent/US9532982B2/en active Active
- 2013-09-18 CA CA2880506A patent/CA2880506C/en active Active
- 2013-09-18 WO PCT/US2013/060292 patent/WO2014047109A1/en not_active Ceased
-
2018
- 2018-09-05 CY CY181100927T patent/CY1120984T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100105711A1 (en) * | 2008-09-10 | 2010-04-29 | Novartis Ag | Organic Compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015111171A (ru) | 2016-11-10 |
| KR102220965B1 (ko) | 2021-02-26 |
| PT2897644T (pt) | 2018-10-16 |
| US20150231124A1 (en) | 2015-08-20 |
| HUE040520T2 (hu) | 2019-03-28 |
| EP2897644B1 (en) | 2018-06-06 |
| BR112015004152A2 (pt) | 2017-07-04 |
| LT2897644T (lt) | 2018-09-25 |
| KR20150056778A (ko) | 2015-05-27 |
| CN104661681A (zh) | 2015-05-27 |
| MX356278B (es) | 2018-05-22 |
| JP6212563B2 (ja) | 2017-10-11 |
| EP2897644A1 (en) | 2015-07-29 |
| JP2015532927A (ja) | 2015-11-16 |
| RU2651023C2 (ru) | 2018-04-18 |
| PL2897644T3 (pl) | 2018-11-30 |
| CN104661681B (zh) | 2018-07-03 |
| CA2880506A1 (en) | 2014-03-27 |
| IN2015DN00735A (enExample) | 2015-07-10 |
| US9532982B2 (en) | 2017-01-03 |
| HRP20181413T1 (hr) | 2018-10-19 |
| ES2686689T3 (es) | 2018-10-19 |
| CA2880506C (en) | 2021-04-20 |
| MX2015003657A (es) | 2015-06-05 |
| CY1120984T1 (el) | 2019-12-11 |
| SI2897644T1 (sl) | 2018-10-30 |
| WO2014047109A1 (en) | 2014-03-27 |
| DK2897644T3 (en) | 2018-09-10 |
| AU2013318205A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230398121A1 (en) | Combination therapy for the treatment of cancer | |
| CA2344090C (en) | Compositions and methods for treating female sexual dysfunction | |
| US20160199365A1 (en) | 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases | |
| AU2013318205B2 (en) | Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor | |
| US20180318275A1 (en) | Combination therapy using pi3k inhibitor and mdm2 inhibitor | |
| WO2020247756A1 (en) | Small molecules to relax uterine smooth muscle contractions | |
| EP4110331B1 (en) | Methods of treating dlbcl using btk inhibitors and combinations thereof | |
| US10328065B2 (en) | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | |
| US20180256557A1 (en) | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |